CareDx

CareDx, Inc. is a precision medicine company based in Brisbane, California, dedicated to innovative healthcare solutions for transplant patients and their caregivers. With over 20 years of experience in transplant care, CareDx is publicly traded on NASDAQ under the ticker symbol "CDNA." The company aims to create life-changing solutions that help transplant patients thrive. CareDx focuses on four main areas: testing services, transplant lab products, digital transplant solutions, and pharma services. Its flagship testing products include AlloSure® Kidney, which detects kidney transplant graft injury, and AlloMap® Heart, a gene expression test for heart transplant monitoring. The company also offers HLA typing solutions to enhance donor-recipient matching and has developed digital tools to optimize transplant management. Additionally, CareDx collaborates with biopharmaceutical companies to support the clinical development of transplant therapies. Led by CEO John W. Hanna, CareDx combines advanced diagnostics and technology to improve transplant outcomes and patient care across various organ types.